Tetany: Possible adverse effect of bevacizumab.

Simple item page
dc.contributor.authorAnwikar, S R
dc.contributor.authorBandekar, M S
dc.contributor.authorPatel, T K
dc.contributor.authorPatel, P B
dc.contributor.authorKshirsagar, N A
dc.date.accessioned2013-01-16T09:57:52Z
dc.date.available2013-01-16T09:57:52Z
dc.date.issued2011-01
dc.description.abstractBackground: Bevacizumab a recombinant humanized monoclonal antibody was approved in 2004 by US FDA for metastatic colorectal cancer. It is reported to cause potentially serious toxicities including severe hypertension, proteinuria, and congestive heart failure. Aim: To correlate adverse event tetany with the use of bevacizumab. Materials and Methods : World Health Organization's Uppsala Monitoring Centre, Sweden, for reporting of adverse drug reactions from all over the world, identified 7 cases with tetany-related symptoms to bevacizumab from four different countries. These 7 patients reported to UMC database developed adverse events described as musculoskeletal stiffness (1), muscle spasm (1), muscle cramps (1), lock jaw or jaw stiffness (4), and hypertonia (1), with hypocalcaemia. Results: After detailed study of the possible mechanism of actions of bevacizumab and factors causing tetany, it is proposed that there is a possibility of tetany by bevacizumab, which may occur by interfering with calcium metabolism. Resorption of bone through osteoclasts by affecting VEGF may interfere with calcium metabolism. Another possibility of tetany may be due to associated hypomagnesaemia, hypokalemia, or hyponatremia. Conclusions: Tetany should be considered as a one of the signs. Patient on bevacizumab should carefully watch for tetany-related symptoms and calcium and magnesium levels for their safety.en_US
dc.identifier.citationAnwikar S R, Bandekar M S, Patel T K, Patel P B, Kshirsagar N A. Tetany: Possible adverse effect of bevacizumab. Indian Journal of Cancer. 2011 Jan-Mar; 48(1): 31-33.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/144408
dc.language.isoenen_US
dc.source.urihttps://www.indianjcancer.com/article.asp?issn=0019-509X;year=2011;volume=48;issue=1;spage=31;epage=33;aulast=Anwikaren_US
dc.subjectBevacizumaben_US
dc.subjectadverse effecten_US
dc.subjecttetanyen_US
dc.subjectserum calciumen_US
dc.subject.meshAged
dc.subject.meshAngiogenesis Inhibitors --adverse effects
dc.subject.meshAntibodies, Monoclonal --adverse effects
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshColorectal Neoplasms --drug therapy
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshSurvival Rate
dc.subject.meshSweden
dc.subject.meshTetany --chemically induced
dc.subject.meshTreatment Outcome
dc.subject.meshVascular Endothelial Growth Factor A --antagonists & inhibitors
dc.subject.meshVascular Endothelial Growth Factor A --immunology
dc.titleTetany: Possible adverse effect of bevacizumab.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijc2011v48n1p31.pdf
Size:
273.19 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Cancer